We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Trial Shows Infants Protected From RSV by Antibody-Based Vaccine
Merck Trial Shows Infants Protected From RSV by Antibody-Based Vaccine
Merck announced that its investigational monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease met its primary safety and efficacy endpoints.